Navigation Links
OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
Date:10/6/2011

BERLIN, October 6, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.

The new Gallium-68-labeled radioactive contrast agent for positron emission tomography (PET) used by SOMscan has the potential to selectively detect and monitor neuroendocrine tumors. Following its potentialregistration, it could be, amongst other applications, used for this indication in conjunction with a new therapeutic drug.

SOMscan binds to four out of five specific receptor subtypes for the naturally-occurring hormone, somatostatin, on the cell surface of neuroendocrine tumors and uses high-resolution combined positron emission tomography and computed tomography (PET/CT) technique. This may allow detection of neuroendocrine tumors and metastases which previously escaped discovery in imaging diagnoses.  The only agent registered to date for the diagnosis of these tumors binds to only one of these receptor subtypes and uses the less sensitive gamma camera technique.

By leveraging high-resolution PET/CT imaging technique, the diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific - with a marked reduction of radiation exposure for the patient. The expectation is that tumors and metastases down to a size of approximately four millimeters can be detected in accurate anatomical correlation with SOMscan. Since both the SOMscan diagnostic and therapeutic agent bind to the same tumor receptors, this makes individual monitoring and management of the course of the disease possible - another step towards personalized medicine… [http://www.octreopharmsciences.com/images/pdf/20111005_ops_pressrelease.pdf].

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Campus Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  udo.blaseg@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
2. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
3. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
6. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
7. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
8. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
9. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
10. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
11. Sangamo BioSciences Announces Presentation at the Sixth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona ... surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new ... Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest ...
(Date:6/23/2016)... ... 2016 , ... vcfo, a consulting firm that provides access ... the promotion of Mike Mackey to Regional Vice President of Southeast Texas. , ... for managing client projects and overseeing vcfo financial consultants in the Houston area. ...
Breaking Medicine News(10 mins):